Abstract
This review will summarize recent developments made in the area of antiviral chemotherapy of rhinovirus and influenza virus infections. It will update previous reviews of this topic1–3 and specifically focus on agents that have been of clinical investigative interest since the previous Symposium three years ago. The only newly approved drug for respiratory viral infections is the anti-influenza agent rimantadine (Flumadine), which has been under study for several decades in the United States. In the USA it was approved in 1993 for prevention of influenza A virus infections in children and adults and for treatment of uncomplicated disease in adults.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
